Publication Details
Abstract
In recent years, there has been a lot of interest in the study for particular biomarkers in ovarian cancer. By targeting tumor suppressors, microRNA-590 has been shown to increase the proliferation of ovarian cancer cells and plays a significant role in the formation of tumors. Numerous cancers, including ovarian cancer, have decreased expression of the tumor suppressor transcription factor FOXA2. The purpose of this study was to assess the diagnostic value of circulating MicroRNA-590 and FOXA2 levels in patients with ovarian cancer. A case-control study comprising 35 healthy controls and 70 ovarian cancer patients was carried out. ELISA was used to measure the levels of FOXA2 in the serum. Using qRT-PCR, the amount of circulating MicroRNA-590 was measured. The 2^-ΔΔCt technique was used to calculate fold change values. ROC curve and logistic regression were used in statistical analysis to compare groups and assess diagnostic value. Compared to controls, ovarian cancer patients had significantly reduced levels of FOXA2 and MicroRNA-590 expression. MicroRNA-590 fold change values were found to have significantly decreased. MicroRNA-590 had an efficient diagnostic value (AUC = 84.5%), according to ROC curve analysis, whereas FOXA2 had limited diagnostic performance. Both indicators' diagnostic significance was validated using logistic regression. MicroRNA-590 and circulating FOXA2 levels are decreased in ovarian cancer and could be useful non-invasive diagnostic indicators. Superior diagnostic accuracy was demonstrated by MicroRNA-590, which may help in early diagnosis and differentiation from healthy individuals.